Sponsor or institution

Clinical trials and research at Pfizer

• 125Clinical trials
• 7New in 30 days
• 50Countries

Newest trials

All recruiting trials (125)

• Marstacimab for mild to moderate hemophilia A or B in people without inhibitors

  This study tests whether weekly injections of marstacimab can reduce bleeding in adolescents and adults with mild to moderate hemophilia A or B who don’t have inhibitors.

  Recruiting Phase 3 Pfizer · Flowood, Mississippi · NCT07923981

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Berobenatide in adults with sleep apnea and obesity who don’t use a PAP machine

  This study tests berobenatide versus placebo in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity who are not using PAP therapy.

  Recruiting at 3 sites Phase 3 Pfizer · Cullman, Alabama and 3 other locations · NCT07881757

• Berobenatide: how it enters the blood after different delivery methods in adults with overweight or obesity

  This study tests a single dose of Berobenatide to see how it behaves in the body when given in different delivery forms to adults with overweight or obesity.

  Recruiting Phase 1 Pfizer · Anaheim, California · NCT07876531

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Switching to a monthly dose of Berobenatide to help keep weight off after weight loss with semaglutide or tirzepatide

  This study tests whether switching to a monthly berobenatide shot can help adults who have overweight or obesity and have already lost weight using semaglutide or tirzepatide to keep the weight off.

  Recruiting at 18 sites Phase 3 Pfizer · Birmingham, Alabama and 25 other locations · NCT07845500

• RSV vaccine in children at high risk to see if it is safe and makes a strong immune response

  This study tests whether the RSVpreF vaccine is safe and helps the immune system in children aged 5 to under 18 who are at high risk for RSV illness, including those who are immunocompromised.

  Recruiting at 11 sites Phase 3 Pfizer · Durham, North Carolina and 19 other locations · NCT07839871

• Berobenatide in adults with sleep apnea and obesity using a PAP machine

  This study tests berobenatide vs. placebo in adults with moderate to severe obstructive sleep apnea and overweight/obesity who use a PAP device.

  Recruiting at 6 sites Phase 3 Pfizer · Cullman, Alabama and 7 other locations · NCT07823608

• RSVpreF vaccine in older adults: safety and immune response

  This study tests the safety and immune response of the RSVpreF vaccine in healthy adults aged 60 and older, with a comparison to placebo in China and RSVpreF given to all participants in the US.

  Recruiting Phase 3 Pfizer · Scottsdale, Arizona and 14 other locations · NCT07819097

• Berobenatide once a month for obesity in adults in Japan

  This study tests whether berobenatide can help adults with obesity in Japan, compared to a placebo, when given as a monthly injection.

  Recruiting at 34 sites Phase 3 Pfizer · Mihama-ku, Chiba and 35 other locations · NCT07794774

• Once-weekly berobenatide in adults with obesity in Japan

  This study tests whether once-weekly berobenatide can be safe and effective for adults with obesity in Japan, compared to a placebo.

  Recruiting at 36 sites Phase 3 Pfizer · Mihama-ku, Chiba and 35 other locations · NCT07794761

• Safety and immune response of three PG4 vaccine lots vs 20vPnC in adults

  This study tests three different lots of a new pneumococcal vaccine and the standard 20vPnC vaccine in adults to see if they are similarly safe and provoke a similar immune response.

  Recruiting at 37 sites Phase 3 Pfizer · Birmingham, Alabama and 36 other locations · NCT07794748

• Weekly medicine versus placebo for overweight or obesity in Chinese adults

  This study tests whether berobenatide given once weekly helps adults in China lose weight compared with a placebo.

  Recruiting at 30 sites Phase 3 Pfizer · Hefei, Anhui and 33 other locations · NCT07792954

• Tilrekimig for moderate-to-severe eczema in teens and adults

  A 52-week study will test tilrekimig against dupilumab and a placebo to see if it helps people 12 and older with moderate-to-severe atopic dermatitis.

  Recruiting at 31 sites Phase 3 Pfizer · Birmingham, Alabama and 49 other locations · NCT07783425

• Tilrekimig for severe asthma

  A Phase 3 test to see if tilrekimig helps people with severe asthma more than a placebo.

  Recruiting at 7 sites Phase 3 Pfizer · Bakersfield, California and 15 other locations · NCT07772921

• Revaccination with RSVpreF in Immunocompromised Adults

  This study tests whether giving an RSVpreF vaccine shot again at about 1, 2, and 3 years is safe and can still provoke an immune response in adults who are immunocompromised.

  Recruiting at 13 sites Phase 3 Pfizer · Los Angeles, California and 16 other locations · NCT07768345

• Safety in pregnancy of PENBRAYA when given during pregnancy or just before

  This registry looks at whether PENBRAYA given during pregnancy or just before the last period is safe for both the mother and her baby.

  Recruiting Pfizer · New York, New York · NCT07768163

• Tilrekimig in adults and teens with eczema too severe for standard creams

  A new medicine called tilrekimig is being tested to see if it helps moderate-to-severe eczema in people 12 and older when used with medicated skin creams.

  Recruiting at 8 sites Phase 3 Pfizer · Birmingham, Alabama and 20 other locations · NCT07765888

• 20vPnC vaccine testing in healthy Chinese infants

  The study tests whether the 20-valent pneumococcal conjugate vaccine is safe and can trigger a protective immune response in healthy babies in China.

  Recruiting at 4 sites Phase 3 Pfizer · Hezhou, Guangxi and 3 other locations · NCT07754539

• Ritlecitinib for patchy hair loss in teens and adults with alopecia areata

  This study tests whether ritlecitinib can help people 12 and older with patchy alopecia areata who have had symptoms for 6 months to 10 years.

  Recruiting at 30 sites Phase 3 Pfizer · Encinitas, California and 37 other locations · NCT07733765

• How different doses of PF-08642534 behave in adults with obesity

  This study tests varying doses of PF-08642534 to see if adults with obesity can take them safely and how the body handles the drug.

  Recruiting Phase 1 Pfizer · Lake Forest, California · NCT07731139

• Daily rimegepant for chronic migraine prevention

  A 12-week test to see if taking rimegepant by mouth every day can reduce monthly migraine days in adults with chronic migraine compared with placebo.

  Recruiting at 18 sites Phase 3 Pfizer · Scottsdale, Arizona and 20 other locations · NCT07729462

• How different particle sizes of Prifetrastat affect how much medicine gets into the blood

  This study tests whether prifetrastat tablets with different active ingredient particle sizes result in different amounts of medicine entering the bloodstream in healthy adults.

  Recruiting Phase 1 Pfizer · Brussels, Bruxelles-capitale, Région de · NCT07721402

• Rimegepant 75 mg ODT for acute migraine in adults in India

  A single-arm study in adults in India will test whether a 75 mg orally disintegrating tablet of rimegepant is safe to use for treating a migraine attack when triptans didn’t work or can’t be used.

  Recruiting at 6 sites Phase 4 Pfizer · Visakhapatnam, Andhra Pradesh and 6 other locations · NCT07685769

• How the medicine Atirmociclib behaves in people with healthy liver or with liver disease

  This study tests how atirmociclib is processed in the body and how safe it is for adults with normal liver function or with stable mild to severe liver disease.

  Recruiting at 3 sites Phase 1 Pfizer · Miami Lakes, Florida and 2 other locations · NCT07677358

• Pfizer medicine PF-08103402: how different doses are tolerated in healthy adults and adults with mild-to-moderate asthma

  This study tests how different amounts of PF-08103402 behave in the body and how well it is tolerated by healthy adults and adults with mild-to-moderate asthma.

  Recruiting at 2 sites Phase 1 Pfizer · New Haven, Connecticut and 1 other locations · NCT07660731

• New pneumococcal vaccine safety and immune response in children and teens

  This study tests whether a new pneumococcal vaccine is as safe and as effective as Prevnar 20 in children and adolescents who have previously received PCV.

  Recruiting at 68 sites Phase 3 Pfizer · Birmingham, Alabama and 76 other locations · NCT07660198

• RSVpreF vaccine in adults: safety and immune response in India

  A Phase 3 test of the RSVpreF vaccine vs placebo in adults 18 and older living in India to see if it is safe and produces an immune response.

  Recruiting at 13 sites Phase 3 Pfizer · Visakhapatnam, Andhra Pradesh and 12 other locations · NCT07653100

• New pneumococcal vaccine in infants shows safety and how it stacks up against Prevnar 20

  A new pneumococcal vaccine is being tested in healthy infants to see if it is as safe as Prevnar 20 and whether it triggers a similar or better immune response.

  Recruiting at 125 sites Phase 3 Pfizer · Bessemer, Alabama and 129 other locations · NCT07629440

• Second dose of rimegepant for acute migraine in adults

  This study tests whether taking a second 75 mg dose of rimegepant is safe and tolerable for adults who still have pain after an initial dose to treat an acute migraine attack.

  Recruiting at 19 sites Phase 4 Pfizer · Canoga Park, California and 23 other locations · NCT07609914

• Berobenatide (PF-08653944) for overweight or obesity in adults

  This study tests whether berobenatide helps adults with overweight or obesity lose weight compared with a placebo.

  Recruiting at 75 sites Phase 3 Pfizer · Canoga Park, California and 79 other locations · NCT07595549

• PF-08634404 plus chemotherapy in adults with advanced or recurrent pMMR endometrial cancer

  This study tests whether PF-08634404 added to standard chemotherapy helps adults with advanced or recurrent pMMR endometrial cancer more than pembrolizumab plus chemotherapy.

  Recruiting at 47 sites Phase 3 Pfizer · Jupiter, Florida and 53 other locations · NCT07578649

• New pneumococcal vaccine for healthy infants

  A new pneumococcal vaccine is being tested in about 2-month-old healthy babies to see if it is as safe as Prevnar 20 and whether it may offer broader protection against germs that cause pneumonia, meningitis, and ear infections.

  Recruiting at 72 sites Phase 3 Pfizer · Estero, Florida and 90 other locations · NCT07573462

• Phase 1 of PF-08046033 for advanced non-small-cell lung cancer, esophageal squamous cell cancer, and cutaneous melanoma

  This Phase 1 study will try the experimental antibody-drug conjugate PF-08046033 in adults whose non-small-cell lung cancer, esophageal squamous cell cancer, or cutaneous melanoma has progressed after standard treatments.

  Recruiting at 20 sites Phase 1 Pfizer · Denver, Colorado and 20 other locations · NCT07519655

• Single-dose PF-08653944 in adults with normal or reduced liver function

  This test gives one injection of PF-08653944 to adults with normal or reduced liver function to see how the body handles the drug and to check safety.

  Recruiting at 3 sites Phase 1 Pfizer · Miami Lakes, Florida and 2 other locations · NCT07519135

• Fifth dose of the 6‑valent OspA Lyme vaccine (VLA15)

  This test gives a fifth dose of the VLA15 Lyme vaccine to people age 7 and older who already got four doses to see if it is safe and boosts immune protection.

  Recruiting at 12 sites Phase 3 Pfizer · Bangor, Maine and 21 other locations · NCT07500506

• PF-08634404 Alone or with chemotherapy in early-stage or locally advanced NSCLC

  This study tests PF-08634404 by itself or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer that may be surgically removable or were candidates for additional therapy after initial treatment.

  Recruiting at 28 sites Phase 2 Pfizer · Huntsville, Alabama and 36 other locations · NCT07489066

• PF-08634404 with or without chemotherapy for adults with transformed small cell lung cancer

  This will try the experimental drug PF-08634404 by itself and together with chemotherapy in adults whose EGFR-mutated non-small cell lung cancer has turned into transformed small cell lung cancer.

  Recruiting at 55 sites Phase 2 Pfizer · Duarte, California and 60 other locations · NCT07476287

• Etrasimod treatment for children with moderately to severely active ulcerative colitis

  This trial tests whether the medicine etrasimod is safe and helps children ages 2 to under 12 with moderately to severely active ulcerative colitis.

  Recruiting at 45 sites Phase 2 Pfizer · Indianapolis, Indiana and 45 other locations · NCT07470879

• mRNA vaccines against influenza in adults

  This research will test single-dose mRNA flu vaccines in healthy adults to see if they are safe and trigger an immune response.

  Recruiting at 15 sites Phase 2 Pfizer · Mobile, Alabama and 14 other locations · NCT07431853

• PF-07994525 in advanced cancers: a first-in-human dose-escalation study

  A single-arm, early-phase study tests PF-07994525 in adults with advanced cancers who have exhausted other therapies to see if it’s safe and shows any signs of tumor activity.

  Recruiting at 29 sites Phase 1 Pfizer · Denver, Colorado and 29 other locations · NCT07426757

• PF-08634404 alone or with enfortumab vedotin for advanced urothelial (bladder) cancer

  This trial will try PF-08634404 by itself or together with enfortumab vedotin to see if it is safe and helps adults with advanced or metastatic urothelial (bladder) cancer.

  Recruiting at 173 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 183 other locations · NCT07421700

• PF-08634404 plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma

  This trial will test whether adding the experimental medicine PF-08634404 to chemotherapy helps adults with newly diagnosed, locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma compared with nivolumab plus chemotherapy.

  Recruiting at 90 sites Phase 2/3 Pfizer · Atascadero, California and 101 other locations · NCT07392892

• PF-07275315 for people with moderate to severe COPD

  This study will test whether PF-07275315, given as clinic injections, helps people aged 35–80 with moderate to severe COPD who have frequent exacerbations while on standard triple inhaled therapy.

  Recruiting at 160 sites Phase 2/3 Pfizer · Birmingham, Alabama and 188 other locations · NCT07363694

• New oral medicine PF-08032562 for advanced or metastatic breast and colorectal cancer

  This trial will try an oral medicine called PF-08032562, given alone or with other cancer drugs, in adults with advanced or metastatic breast or colorectal cancer.

  Recruiting at 13 sites Phase 1 Pfizer · Duarte, California and 16 other locations · NCT07318805

• How the body processes PF-07328948 in people with normal or reduced kidney function

  We will give a single oral dose of PF-07328948 to adults with normal or moderately-to-severely reduced kidney function to see how their bodies process the medicine and how well they tolerate it.

  Recruiting at 4 sites Phase 1 Pfizer · Lake Forest, California and 3 other locations · NCT07315360

• Clostridioides difficile vaccine for people 65 and older

  This trial tests whether a vaccine can prevent C. difficile infections in people age 65 and older.

  Recruiting at 183 sites Phase 3 Pfizer · Athens, Alabama and 184 other locations · NCT07282665

• How PF-07328948 is processed in people with and without reduced liver function

  Adults with and without reduced liver function will take a single dose of PF-07328948 to see how their bodies process the medicine.

  Recruiting at 3 sites Phase 1 Pfizer · Lake Forest, California and 2 other locations · NCT07269301

• Testing different doses of PF-08065010 in healthy adults

  This study tests whether PF-08065010 is safe and how it behaves in the body, comparing it to a placebo in healthy adults aged 18 to 65.

  Recruiting Phase 1 Pfizer · Brussels, Bruxelles-capitale, Région de · NCT07235163

• How vepdegestrant is processed in people with reduced liver function

  This test gives a single oral dose of vepdegestrant to adults with normal or reduced liver function to see how their bodies process the medicine.

  Recruiting at 4 sites Phase 1 Pfizer · Miami, Florida and 3 other locations · NCT07231991

• PF-08634404 alone and with other anticancer medicines for adults with advanced kidney cancer.

  This tests whether PF-08634404, given alone or with other cancer medicines, is safe and helps adults with locally advanced or metastatic kidney cancer who have not had prior systemic treatment.

  Recruiting at 157 sites Phase 1/2 Pfizer · Phoenix, Arizona and 182 other locations · NCT07227415

• PF-08634404 combined with other cancer medicines for advanced non-small cell lung cancer

  This will test whether PF-08634404 given with other cancer medicines is safe and can help adults with advanced or metastatic non-small cell lung cancer.

  Recruiting at 85 sites Phase 1/2 Pfizer · Fayetteville, Arkansas and 103 other locations · NCT07227298

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• PF-08634404 plus chemotherapy for extensive-stage small cell lung cancer

  This study will try adding PF-08634404 to chemotherapy in adults with extensive-stage small cell lung cancer to see if it works better than current first-line treatment.

  Recruiting at 82 sites Phase 2/3 Pfizer · Fayetteville, Arkansas and 81 other locations · NCT07226999

• PF-08634404 plus chemotherapy for adults with metastatic colorectal cancer

  This trial will test whether adding a new drug called PF-08634404 to standard chemotherapy helps adults whose colorectal cancer has spread.

  Recruiting at 343 sites Phase 3 Pfizer · Chandler, Arizona and 371 other locations · NCT07222800

• PF-08634404 plus chemotherapy versus pembrolizumab-based chemotherapy for advanced non-small cell lung cancer

  This will test whether PF-08634404 combined with chemotherapy works better than pembrolizumab plus chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer who have not received prior treatment for their advanced disease.

  Recruiting at 464 sites Phase 3 Pfizer · Bullhead City, Arizona and 483 other locations · NCT07222566

• Ritlecitinib for chronic spontaneous urticaria (chronic hives) in adults

  This trial will try daily oral ritlecitinib (50 mg or 100 mg) to see if it reduces hives and itching in adults with chronic spontaneous urticaria not controlled by antihistamines.

  Recruiting at 77 sites Phase 2 Pfizer · Phoenix, Arizona and 76 other locations · NCT07219615

• A medicine for eczema: see if PF-08049820 helps adults with moderate to severe atopic dermatitis

  This study tests whether PF-08049820, taken as a daily pill, can safely help adults with moderate to severe eczema compared to a placebo.

  Recruiting at 41 sites Phase 2 Pfizer · Phoenix, Arizona and 51 other locations · NCT07216027

• Testing PF-08052667 for high-risk non-muscle invasive bladder cancer

  This study will test whether the new medicine PF-08052667, alone or with BCG and/or sasanlimab, helps adults with high-risk non-muscle invasive bladder cancer that has come back or not responded to standard treatment.

  Recruiting at 66 sites Phase 1 Pfizer · Birmingham, Alabama and 68 other locations · NCT07206225

• BEATRIX: group B streptococcus (GBS) vaccine for pregnant women and their babies

  This will test a single shot of a 6‑valent group B strep vaccine (or a saline placebo) in healthy pregnant women at 24–36 weeks to see if it's safe and produces protective responses in mothers and their babies.

  Recruiting at 211 sites Phase 3 Pfizer · Birmingham, Alabama and 218 other locations · NCT07160244

• Litfulo capsule for people with severe alopecia areata in routine care

  People aged 12 and older with severe alopecia areata who start Litfulo capsules will be followed in routine clinics to see if the medicine is safe and what effects it has.

  Recruiting Pfizer · Seoul · NCT07152119

• PF-08046054 (SGN-PDL1V) versus docetaxel for PD-L1–positive advanced non-small cell lung cancer

  This test compares PF-08046054 (SGN-PDL1V) with docetaxel for adults whose PD-L1–positive advanced NSCLC progressed after PD-1/PD-L1 inhibitors, platinum chemotherapy, and targeted treatments when appropriate.

  Recruiting at 454 sites Phase 3 Pfizer · Alabaster, Alabama and 468 other locations · NCT07144280

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• PF-07248144 plus fulvestrant for HR-positive, HER2-negative advanced or metastatic breast cancer after prior treatment

  This will test whether adding the experimental drug PF-07248144 to fulvestrant helps people with HR-positive, HER2-negative advanced or metastatic breast cancer who have progressed after prior therapies, including CDK4/6 inhibitors.

  Recruiting at 433 sites Phase 3 Pfizer · Anchorage, Alaska and 432 other locations · NCT07062965

• Long-term ritlecitinib treatment for children with severe alopecia areata

  This study will give ritlecitinib to children who completed earlier Pfizer pediatric ritlecitinib studies to see if long-term treatment is safe and helps maintain or improve hair regrowth.

  Recruiting at 56 sites Phase 3 Pfizer · Irvine, California and 66 other locations · NCT07029828

• Mevrometostat plus enzalutamide versus enzalutamide alone for men with metastatic castration‑sensitive prostate cancer who are ARPI‑naïve

  This trial will test whether adding the investigational drug mevrometostat to enzalutamide helps men with metastatic castration‑sensitive prostate cancer who have not received androgen receptor pathway inhibitors or chemotherapy.

  Recruiting at 145 sites Phase 3 Pfizer · Huntsville, Alabama and 318 other locations · NCT07028853

• Ibuzatrelvir alone or with remdesivir for severely immunocompromised adults with COVID-19

  This will test whether ibuzatrelvir, taken alone or together with remdesivir, helps severely immunocompromised adults who recently developed COVID-19 symptoms.

  Recruiting at 148 sites Phase 3 Pfizer · Canoga Park, California and 158 other locations · NCT07013474

• Zavegepant (nasal spray) for treating migraine in children 6 to under 12

  This trial will test a single weight-based dose of zavegepant nasal spray to see how safe it is and how the medicine is processed in children 6 to under 12 with migraine.

  Recruiting at 11 sites Phase 1 Pfizer · Washington D.C., District of Columbia and 13 other locations · NCT06995729

• PF-07328948 for adults with heart failure (BRANCH-HF).

  This trial will test whether taking PF-07328948 once daily helps adults with heart failure who are already on standard medicines, including SGLT2 inhibitors.

  Recruiting at 141 sites Phase 2 Pfizer · Beverly Hills, California and 149 other locations · NCT06991257

• Ponsegromab plus chemotherapy for adults with metastatic pancreatic cancer and cachexia

  This trial tests whether adding the monoclonal antibody ponsegromab to first-line chemotherapy helps adults with metastatic pancreatic cancer who are losing weight and have fatigue from cachexia.

  Recruiting at 214 sites Phase 2/3 Pfizer · Birmingham, Alabama and 229 other locations · NCT06989437

• Investigating PF-07275315 for treating moderate-to-severe asthma

  This study is testing a new medication called PF-07275315 to see if it can help adults with moderate-to-severe asthma feel better and have fewer asthma attacks.

  Recruiting at 126 sites Phase 2 Pfizer · Mobile, Alabama and 136 other locations · NCT06977581

• Exploring TIVDAK for Women with Recurrent Cervical Cancer

  This study is testing a treatment called TIVDAK for women whose cervical cancer has come back after chemotherapy to see how it affects their health, especially their eyes.

  Recruiting at 130 sites Phase 4 Pfizer · Phoenix, Arizona and 134 other locations · NCT06952660

• Abrocitinib for moderate-to-severe atopic dermatitis after inadequate response to biologics

  This study will try abrocitinib in adolescents and adults (≥12 years) with moderate-to-severe atopic dermatitis who didn't respond to or couldn't tolerate up to two biologic treatments to see how it works in routine care.

  Recruiting Pfizer · San Diego, California · NCT06899204

• Testing two doses of ritlecitinib for treating alopecia areata in people aged 12 and older

  This study is testing two different doses of a new oral medication called ritlecitinib to see if it can help people aged 12 and older with significant hair loss from alopecia areata.

  Recruiting at 41 sites Phase 3 Pfizer · Birmingham, Alabama and 147 other locations · NCT06873945

• Revaccination with RSV vaccine during subsequent pregnancies

  This study is testing if giving a second dose of the RSV vaccine to pregnant women who already had it is safe and effective for them and their babies.

  Recruiting at 96 sites Phase 3 Pfizer · Birmingham, Alabama and 96 other locations · NCT06866405

• Long-term abrocitinib oral suspension treatment for children 2 years and older with moderate-to-severe eczema

  This 24-month trial will try a liquid form of the medicine abrocitinib, with or without topical medicines, in children aged 2 years and older who have moderate-to-severe eczema to see if it is safe and helps their skin over time.

  Recruiting at 34 sites Phase 3 Pfizer · Birmingham, Alabama and 39 other locations · NCT06807281

• Abrocitinib treatment for children 6 to under 12 with moderate-to-severe eczema

  We will test whether the medicine abrocitinib helps children aged 6 to under 12 with moderate-to-severe eczema and is safe.

  Recruiting at 47 sites Phase 3 Pfizer · Birmingham, Alabama and 46 other locations · NCT06807268

• Safety monitoring of Prevenar 20 in people in Korea

  This project will see if the Prevenar 20 vaccine is safe for people in the Republic of Korea aged 6 weeks and older who are prescribed it.

  Recruiting Pfizer · Seoul · NCT06760208

• Combining Sigvotatug Vedotin and Pembrolizumab for Non-Small Cell Lung Cancer

  This study is testing a new combination of two treatments, Sigvotatug Vedotin and pembrolizumab, to see if it helps people with advanced non-small cell lung cancer feel better compared to just using pembrolizumab alone.

  Recruiting at 355 sites Phase 3 Pfizer · Fullerton, California and 388 other locations · NCT06758401

• Switching from Emicizumab to Marstacimab in Severe Hemophilia A

  This study is testing if switching from emicizumab to marstacimab is safe and how well the body handles the new medication in people with severe hemophilia A.

  Recruiting at 7 sites Phase 1 Pfizer · La Jolla, California and 9 other locations · NCT06703606

• Understanding how dazukibart works in patients with inflammatory muscle diseases

  This study is testing how well the medication dazukibart works for people with inflammatory muscle diseases like dermatomyositis and polymyositis to see if it helps reduce muscle inflammation and improve strength.

  Recruiting at 24 sites Phase 3 Pfizer · Glendale, Arizona and 25 other locations · NCT06698796

• Evaluating ibuzatrelvir for treating non-hospitalized COVID-19 patients at risk for severe disease

  This study is testing if a new medication called ibuzatrelvir can help adults and teens with COVID-19 who are not in the hospital but are at high risk for getting worse.

  Recruiting at 236 sites Phase 3 Pfizer · Huntsville, Alabama and 255 other locations · NCT06679140

• Using Rimegepant to prevent menstrual migraines in women

  This study is testing if rimegepant can help women with a history of menstrual migraines have fewer and less severe headaches during their periods.

  Recruiting at 123 sites Phase 3 Pfizer · Phoenix, Arizona and 122 other locations · NCT06641466

• Investigating PF-06821497 for men with advanced prostate cancer

  This study is testing if a new drug called PF-06821497 can help men with advanced prostate cancer feel better when used with a standard treatment compared to a placebo.

  Recruiting at 203 sites Phase 3 Pfizer · Chandler, Arizona and 230 other locations · NCT06629779

• Learning about Somatrogon for treating growth hormone deficiency in children in India

  This study is testing the safety of a new growth hormone injection called Somatrogon in children with growth hormone deficiency in India.

  Recruiting at 4 sites Pfizer · Bengaluru, Karnataka and 3 other locations · NCT06587035

• Evaluating PF-07832837 for safety and tolerability in healthy adults and patients with atopic dermatitis

  This study is testing a new drug called PF-07832837 to see if it's safe and tolerable for both healthy adults and adults with moderate to severe atopic dermatitis.

  Recruiting at 5 sites Phase 1 Pfizer · Anaheim, California and 7 other locations · NCT06564389

• Taste and how osivelotor gets into the blood with or without food

  This study tests how osivelotor tastes and how well it is absorbed in healthy adults when taken with food, liquids, or an antacid.

  Recruiting Phase 1 Pfizer · Brussels, Bruxelles-capitale, Région de · NCT06507904

• Effectiveness and safety of Lorlatinib for untreated ALK-positive lung cancer patients in France

  This study is testing if Lorlatinib is safe and effective for adults in France who have not yet received treatment for ALK-positive lung cancer.

  Recruiting at 23 sites Pfizer · Toulouse, Haute-garonne and 31 other locations · NCT06487078

• Evaluating Aztreonam-Avibactam for Treating Bacterial Infections in Infants and Newborns

  This study is testing a new antibiotic combination to see if it is safe and effective for treating bacterial infections in hospitalized infants and newborns.

  Recruiting at 30 sites Phase 2 Pfizer · Orange, California and 31 other locations · NCT06462235

• Observing the effects of etrasimod in adults with moderate to severe ulcerative colitis

  This study is testing how well etrasimod works for adults with moderate to severe ulcerative colitis by tracking their symptoms over a year while they use the medication as part of their regular treatment.

  Recruiting at 24 sites Pfizer · Mesa, Arizona and 28 other locations · NCT06398626

• Bosulif treatment for adults with chronic myeloid leukemia

  This project will try bosulif in adults with Philadelphia chromosome–positive chronic myeloid leukemia in routine care to see if it is safe and works well.

  Recruiting Pfizer · New York, New York · NCT06297161

• Evaluating Elranatamab for Relapsed Multiple Myeloma

  This study tests if a new treatment called elranatamab can help people with relapsed multiple myeloma feel better compared to standard therapies they might have already tried.

  Recruiting at 222 sites Phase 3 Pfizer · Mobile, Alabama and 269 other locations · NCT06152575

• Access to Elranatamab for Multiple Myeloma Patients

  This study is providing continued access to the treatment elranatamab for people with Multiple Myeloma who have already seen benefits from it in earlier trials.

  Recruiting at 31 sites Phase 4 Pfizer · Irvine, California and 32 other locations · NCT06057402

• Understanding how PF-06823859 works in patients with muscle inflammation disorders

  This study is testing a new medication called PF-06823859 to see if it can help adults with muscle inflammation disorders like dermatomyositis and polymyositis feel better compared to a placebo.

  Recruiting at 125 sites Phase 3 Pfizer · Glendale, Arizona and 137 other locations · NCT05895786

• Observing the safety and effectiveness of Paxlovid in patients at high risk for severe COVID-19

  This study is testing how safe and effective Paxlovid is for people in Korea who are at high risk of getting severe COVID-19 and have mild-to-moderate symptoms.

  Recruiting Pfizer · Seoul · NCT05890612

• Xeljanz safety and effects in Korean children with juvenile idiopathic arthritis

  This will try Xeljanz in children and teens (ages 2 to under 18) with juvenile idiopathic arthritis in Korea to see how safe and helpful it is during routine care.

  Recruiting Pfizer · Seoul · NCT05754710

• Evaluating Inotuzumab Ozogamicin for Children with Relapsed Acute Lymphoblastic Leukemia

  This study is testing if a new drug called Inotuzumab Ozogamicin can help children with relapsed acute lymphoblastic leukemia do better than the usual treatment.

  Recruiting at 65 sites Phase 2 Pfizer · Vienna and 64 other locations · NCT05748171

• Learning about the safety and effectiveness of Zavicefta in Korea

  This study is trying to learn how safe and effective Zavicefta is for treating serious infections in both adults and kids in Korea after it has been released for use.

  Recruiting Pfizer · Seoul, Gangnam-gu · NCT05733104

• Safety of Abrocitinib in Pregnant Women and Their Babies

  This study is testing whether the medication abrocitinib is safe for pregnant women and their babies compared to women with similar skin conditions who haven't taken the drug.

  Recruiting Pfizer · New York, New York · NCT05721937

• Learning about Abrocitinib for treating moderate to severe atopic dermatitis in adults

  This study is testing if taking Abrocitinib daily can safely help adults with moderate to severe atopic dermatitis feel better over two years.

  Recruiting at 30 sites Pfizer · Amiens, Somme and 29 other locations · NCT05689151

• Comparing Aztreonam and Avibactam to Standard Therapy for Serious Infections in Children

  This study is testing if two new medications, Aztreonam and Avibactam, can help children with serious bacterial infections feel better compared to the usual treatments they receive.

  Recruiting at 20 sites Phase 2 Pfizer · San Diego, California and 21 other locations · NCT05639647

• Evaluating new treatment combinations for newly diagnosed multiple myeloma patients not eligible for transplant

  This study is testing different combinations of medications for people with newly diagnosed multiple myeloma who can't have a transplant to see which one works best and is safest.

  Recruiting at 170 sites Phase 3 Pfizer · Daphne, Alabama and 179 other locations · NCT05623020

• Testing marstacimab for treating hemophilia in children

  This study is testing a new medication called marstacimab to see if it can help children with severe hemophilia control their bleeding and improve their health.

  Recruiting at 51 sites Phase 3 Pfizer · Salt Lake City, Utah and 62 other locations · NCT05611801

• Monitoring the use of Lorviqua for lung cancer in Korea

  This study looks at how well Lorviqua works and its side effects in people with a specific type of lung cancer in Korea.

  Recruiting Pfizer · Seoul · NCT05599412

• Evaluating the safety and effectiveness of gene therapies for Hemophilia A and B

  This study is testing two gene therapies for Hemophilia A and B to see how safe and effective they are for patients who have already taken part in previous trials.

  Recruiting at 36 sites Phase 3 Pfizer · Rancho Cordova, California and 38 other locations · NCT05568719

• Learning how the 20-valent pneumococcal vaccine works against pneumonia

  This study is trying to see if the 20-valent pneumococcal vaccine can help prevent pneumonia in people aged 65 and older who are hospitalized with suspected pneumonia.

  Recruiting at 53 sites Pfizer · El Centro, California and 53 other locations · NCT05452941

• Phase 2/3 testing of osivelotor in adults and adolescents with sickle cell disease.

  This trial tests whether an oral medicine called osivelotor can safely reduce pain crises and improve blood measures in people aged 12–65 with sickle cell disease.

  Recruiting at 38 sites Phase 2/3 Pfizer · Mobile, Alabama and 79 other locations · NCT05431088

• Observing the effects of Cibinqo in patients with atopic dermatitis

  This study is testing how well Cibinqo works and how safe it is for people aged 12 and older with moderate to severe atopic dermatitis in Korea over about a year.

  Recruiting Pfizer · Seoul · NCT05391061

• Evaluating Etrasimod for Treating Ulcerative Colitis in Adolescents

  This study is testing if a new medication called etrasimod can help teenagers with moderate to severe ulcerative colitis feel better over a year and possibly longer.

  Recruiting at 39 sites Phase 2 Pfizer · Little Rock, Arkansas and 46 other locations · NCT05287126

• Learning about a COVID-19 treatment for children at risk of severe disease

  This study is testing a COVID-19 medication to see if it helps children under 18 who are at risk for severe illness feel better and avoid serious complications.

  Recruiting at 5 sites Phase 3 Pfizer · Phoenix, Arizona and 72 other locations · NCT05261139

• Continued access to encorafenib and binimetinib for previous trial participants

  This study is for people who have previously taken the medications encorafenib and binimetinib and want to continue using them safely for up to five years if they are still benefiting from the treatment.

  Recruiting at 62 sites Phase 4 Pfizer · Phoenix, Arizona and 76 other locations · NCT05203172

• Learning about the safety of Mylotarg in patients with acute myeloid leukemia

  This study is testing how safe Mylotarg is for adults who have just been diagnosed with acute myeloid leukemia while they receive it as part of their regular treatment.

  Recruiting Pfizer · Seoul · NCT05189639

• Preventing migraines in children with rimegepant

  This study is testing if a new medication called rimegepant can help kids and teens aged 6 to 17 who get migraines by reducing how often they have them and improving their quality of life.

  Recruiting at 61 sites Phase 3 Pfizer · Fort Smith, Arkansas and 92 other locations · NCT05156398

• Long-term treatment with marstacimab for hemophilia patients

  This study is testing a long-term treatment called marstacimab to see if it can safely help people with severe hemophilia A or B manage their condition better.

  Recruiting at 68 sites Phase 3 Pfizer · Iowa City, Iowa and 77 other locations · NCT05145127

• Evaluating outcomes for mothers and infants after exposure to Rimegepant during pregnancy

  This study is trying to see how taking the migraine medication Rimegepant during pregnancy affects the health of mothers and their babies compared to those who didn't take it.

  Recruiting Pfizer · Wilmington, North Carolina · NCT05046613

• Elranatamab alone or with daratumumab for people with multiple myeloma after prior treatment

  This trial will test whether the BCMA-targeting drug elranatamab alone or together with daratumumab helps people with multiple myeloma who have already been treated with lenalidomide, compared with daratumumab plus pomalidomide and dexamethasone.

  Recruiting at 80 sites Phase 3 Pfizer · Clovis, California and 236 other locations · NCT05020236

• Monitoring the safety and effectiveness of Xeljanz XR in patients with certain types of arthritis

  This study is testing how safe and effective the medication Xeljanz XR is for people in Korea with certain types of arthritis, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

  Recruiting Pfizer · Seoul · NCT04876781

• Long-term safety of rimegepant for treating migraines in children

  This study is testing the long-term safety of rimegepant, a migraine medication, for children and teens aged 6 to under 18 who have frequent migraine attacks.

  Recruiting at 61 sites Phase 3 Pfizer · Scottsdale, Arizona and 123 other locations · NCT04743141

• Testing a new treatment for migraines in children and adolescents

  This study is testing a new migraine medication for kids and teens to see if it helps them feel better compared to a sugar pill.

  Recruiting at 122 sites Phase 3 Pfizer · Birmingham, Alabama and 245 other locations · NCT04649242

• Evaluating PF-07248144 for advanced solid tumors

  This study is testing a new drug called PF-07248144 to see if it can safely help people with advanced solid tumors, like certain types of breast, prostate, and lung cancers.

  Recruiting at 40 sites Phase 2 Pfizer · Scottsdale, Arizona and 42 other locations · NCT04606446

• Testing a new drug for advanced solid tumors

  This study is testing a new drug for people with advanced solid tumors, like breast or prostate cancer, to see how safe it is and how well it works on its own or with other treatments.

  Recruiting at 11 sites Phase 2 Pfizer · Los Angeles, California and 38 other locations · NCT04557449

• Treatment of advanced cancers with Mevrometostat

  This study is testing a new drug called Mevrometostat to see if it can help people with advanced cancers like small cell lung cancer, prostate cancer, and follicular lymphoma feel better and improve their treatment outcomes.

  Recruiting at 22 sites Phase 1 Pfizer · Tucson, Arizona and 84 other locations · NCT03460977

Quick answers

How many clinical trials run by Pfizer are recruiting right now?

125, as of November 12, 2026. 7 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 50 countries. The most sites are in United States (102 trials), Japan (56 trials), Spain (52 trials), China (46 trials), South Korea (37 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 57, Phase 1: 21, Phase 2: 14, Phase 2/3: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →